首页> The lancet. Diabetes & endocrinology> Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial.

导出 LinkOut

翻译打印收藏纠错

第一作者： Julius Simoni,Leere

第一单位： Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. Electronic address: j.leere@rn.dk.

作者： Julius Simoni,Leere ^[1] ; Jesper,Karmisholt ^[2] ; Maciej,Robaczyk ^[3] ; Simon,Lykkeboe ^[4] ; Aase,Handberg ^[5] ; Emilie,Steinkohl ^[6] ; Jens,Brøndum Frøkjær ^[6] ; Peter,Vestergaard ^[7]

作者单位： Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. Electronic address: j.leere@rn.dk. ^[1] Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; Department of Endocrinology, Aalborg University, Aalborg, Denmark. ^[2] Department of Endocrinology, Aalborg University, Aalborg, Denmark. ^[3] Department of Clinical Biochemistry, Aalborg University, Aalborg, Denmark. ^[4] Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; Department of Clinical Biochemistry, Aalborg University, Aalborg, Denmark. ^[5] Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; Department of Radiology, Aalborg University, Aalborg, Denmark. ^[6] Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; Department of Endocrinology, Aalborg University, Aalborg, Denmark; Steno Diabetes Center North Jutland, Aalborg, Denmark. ^[7]

医学主题词老年人(Aged);骨密度(Bone Density);骨重建(Bone Remodeling);双盲法(Double-Blind Method);女(雌)性(Female);人类(Humans);甲状旁腺功能亢进, 原发性(Hyperparathyroidism, Primary);男(雄)性(Male);中年人(Middle Aged)

DOI 10.1016/S2213-8587(20)30063-2

PMID 32333877

发布时间 2020-07-17

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

The lancet. Diabetes & endocrinology

2020年8卷5期

407-417页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览2

点击下载本期目录封面

The lancet. Diabetes & endocrinology

2020年8卷5期

407-417页

检索历史清除

Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial.

The lancet. Diabetes & endocrinology

相似文献

同项目论文

The lancet. Diabetes & endocrinology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial.

The lancet. Diabetes & endocrinology

相似文献

同项目论文

The lancet. Diabetes & endocrinology

相关期刊

检索历史清除